After the patient developed progressive apathy, loss of initiative, magnetic gait and hypertonia of the extremities, treatment with dexamethasone (2 × 4 mg/day) was started. There was a ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Patna: International Epilepsy Day, observed on the second Monday of Feb since 2015, aims to educate the public, break the ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...

How former NFL players are teaming with a Peninsula med-tech company on a game plan for long-term heart health ...

One of the NFL's most influential agents for years, Leigh Steinberg is now aiming to support emerging approaches for head ...

Fifteen studies (online supplemental table 1) including 1408 patients with cirrhosis and variceal bleeding (1252 (88.9%) for secondary prophylaxis, 120 (8.5%) for acute treatment and 36 (2.6%) for ...

(1) The total number of outstanding shares of the Company on 24 January 2025 mentioned in the relevant transparency notifications amounts to 52,416,601, each share giving right to one (1) vote (being ...

1 Department of Paediatric Neurology, Sheffield Children's Hospital, NHS Foundation Trust, Sheffield, UK 2 Department of Paediatric Neuroradiology, Sheffield Children's Hospital, NHS Foundation Trust, ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...